Sugimoto, Shinya

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Gastroenterology and Hepatology) ( Shinanomachi )

Position

Instructor
Scopus Paper Info  
Paper Count: 96 Citation Count: 4949 h-index: 31

Click to view the Scopus page. The data was downloaded from Scopus API in October 25, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲

Academic Background 【 Display / hide 】

  • 2003.04
    -
    2009.03

    Keio University, School of Medicine

    University, Graduated

  • 2014.04
    -
    2018.03

    Keio University, 医学研究科医学研究系専攻

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, Keio University, Coursework, 2018.03

    Reconstruction of the Human Colon Epithelium In Vivo

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Gastroenterology

Page Top ▲

Research Keywords 【 Display / hide 】

  • オルガノイド

  • 潰瘍性大腸炎関連腫瘍

  • 炎症性腸疾患

  • 短腸症候群

  • 腸管上皮幹細胞

Page Top ▲
 

Books 【 Display / hide 】

  • Organoid derivation and orthotopic xenotransplantation for studying human intestinal stem cell dynamics

    Sugimoto S., Fujii M., Sato T., Methods in Molecular Biology, 2020

    　View Summary

    Intestinal stem cells continuously self-renew throughout life to maintain gut homeostasis. With the advent of the organoid culture system, we are now able to indefinitely expand healthy and diseased tissue-derived human intestinal stem cells in vitro and use them for various applications. Nonetheless, investigating the behavior of human intestinal stem cells in vivo still remains challenging. We recently developed an orthotopic xenotransplantation system that realizes in vivo reconstruction of human intestinal epithelial tissue with preserved stem cell hierarchy by engrafting human normal colon organoids onto the mouse colon surface. We also introduced new growth factors, namely, insulin-like growth factor-1 (IGF-1) and fibroblast growth factor-2 (FGF-2), into the culture condition for human intestinal organoids that significantly increase scalability and transfectability of the organoids. By integrating these recent advances, we organized a tissue-oriented platform encompassing derivation of patient-derived intestinal organoids and their orthotopic xenotransplantation. The research platform based on orthotopic xenotransplantation of human intestinal organoids provides a powerful tool for studying human intestinal stem cell biology in native tissue-relevant contexts as well as for establishing novel disease modeling systems.

  • Establishment of 3D intestinal organoid cultures from intestinal stem cells

    Sugimoto S., Sato T., Methods in Molecular Biology, 2017

    　View Summary

    The intestinal epithelium is the most rapidly renewed tissue in adult mammals, and its renewal is strictly controlled by intestinal stem cells. Extensive studies using genetic models of intestinal epithelium have revealed the mechanisms underlying the self-renewal of intestinal stem cells. Exploiting this knowledge, we developed a novel 3D culture system that enables the outgrowth of intestinal Lgr5+ stem cells derived from mouse and human tissues into ever-expanding crypt–villus mini-guts, known as intestinal epithelial organoids. These organoids are maintained by the self-renewal of stem cells and give rise to all differentiated cell types of the intestinal epithelium. Once established, organoids can be cryopreserved and thawed when needed. This culture system has been widely used for studying stem cell behavior and gene function and for disease modeling.

Page Top ▲

Papers 【 Display / hide 】

  • Updated Protocols for 3D and 2D Culture and Histological Analysis of Intestinal Organoids.

    Hanyu H, Sugimoto S, Sato T

    Methods in molecular biology (Clifton, N.J.) 3059   125 - 138 2027

    ISSN  1064-3745

  • Diagnostic Performance and Reproducibility of Chromoendoscopic Classification (FOCUS Classification: Flat-Type Dysplasia Optical Assessment by Chromoendoscopy in Ulcerative ColitiS) for Flat-Type Dysplasia in Ulcerative Colitis–Associated Neoplasia

    Takabayashi K., Murata S., Sasaki M., Miyazaki K., Masunaga T., Kirita K., Mizutani M., Yoshimatsu Y., Takatori Y., Akimoto T., Kiyohara H., Sugimoto S., Kawasaki S., Mikami Y., Matsuura N., Nakayama A., Sujino T., Ito Y., Yamanoi K., Sekine S., Iwao Y., Yahagi N., Kanai T., Kato M.

    Digestive Endoscopy 38 ( 9 ) e70280 2026.09

    ISSN  09155635

    　View Summary

    Objectives: Ulcerative colitis-associated neoplasia (UCAN) often presents as flat-type dysplasia that is difficult to characterize endoscopically. We developed a FOCUS (Flat-type dysplasia Optical assessment by Chromoendoscopy in Ulcerative colitiS) classification and evaluated its diagnostic performance and reproducibility. Methods: This single-center retrospective study included 33 UCAN lesions from 26 patients. Prospectively recorded FOCUS classifications at 230 biopsy sites were compared with histopathology. Chromoendoscopic patterns were categorized as Type I (“suggestive of non-dysplasia,”), Type II (“suggestive of dysplasia with low confidence”), or Type III (“suggestive of dysplasia with high confidence”). Diagnostic performance was assessed using two prespecified thresholds: Types II/III versus Type I and Type III versus Types I/II. Eight endoscopists independently classified all images; interobserver and intraobserver agreement were assessed using Fleiss' and Cohen's κ, respectively. Results: The dysplasia-bearing rate increased stepwise from Type I to Type III (Type I 15.5%, Type II 58.3%, Type III 81.8%). Using the primary threshold, sensitivity was 82.0%, and specificity 75.4% (positive likelihood ratio 3.33; negative likelihood ratio 0.24). Interobserver agreement for the three-category classification was moderate to substantial (Fleiss' κ 0.629; 95% CI 0.545–0.712), and median intraobserver agreement was substantial (Cohen's κ 0.738). Conclusions: The FOCUS classification provides clinically meaningful risk stratification for flat-type dysplasia in a high-risk UCAN cohort, with acceptable interobserver and intraobserver reproducibility.

  • Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.

    Okada H, Sugimoto S, Kayashima A, Mikami Y, Kanai T, Nakamoto N, Keio PSC–IBD Collaborators

    Journal of gastroenterology 61 ( 7 ) 863 - 879 2026.03

    ISSN  0944-1174

    　View Summary

    Primary sclerosing cholangitis (PSC) is frequently accompanied by colitis with clinicopathologic features that differ from conventional inflammatory bowel disease (IBD). Accumulating evidence indicates that PSC-associated IBD (PSC-IBD) often presents as extensive colitis with a right-sided predominant distribution and characteristic endoscopic features, such as rectal sparing and backwash ileitis. Beyond endoscopic appearance, PSC-IBD also appears to have distinct biological underpinnings, including shared genetic susceptibility, dysregulated bile acid signaling, altered gut microbial communities, and immune crosstalk along the gut–liver axis. These mechanisms may contribute not only to intestinal inflammation but also to PSC-related clinical outcomes. From a long-term perspective, patients with PSC and colitis are consistently classified as a high-risk group for colorectal neoplasia, warranting early and intensive colonoscopic surveillance. In parallel, surveillance for hepatobiliary malignancies remains central in PSC care, although risk stratification continues to evolve. Therapeutic management generally follows established IBD algorithms, yet the extent to which colitis-directed therapies modify PSC outcomes remains uncertain, with heterogeneous findings across cohorts and endpoints. In this review, we summarize current knowledge on the clinical phenotype, mechanistic framework, and outcome-driven management of PSC-IBD, and highlight future directions toward precision surveillance and mechanism-based interventions targeting bile acid–microbiota–immune interactions.

  • Evaluation of drug-induced lymphocyte stimulation test in mesalazine-associated allergic drug reaction

    Fukasawa N., Kiyohara H., Adachi T., Sugimoto S., Yoshimatsu Y., Murakami S., Mizushima I., Kaieda Y., Takabayashi K., Tsunoda J., Nakamoto N., Fukunaga K., Taguri M., Mikami Y., Kanai T.

    Journal of Allergy and Clinical Immunology Global 5 ( 2 ) 100625 2026.03

    　View Summary

    Background: 5-Aminosalicylic acid (5-ASA) is a fundamental drug for UC management; however, adverse reactions can lead to poor clinical outcomes and increased health care costs. No objective tests currently exist to predict adverse reactions. This study thus investigated 5-ASA across 4 formulations and addressed a key issue in the treatment of mild to moderate ulcerative colitis (UC). Objective: We aimed to examine the utility of the drug-induced lymphocyte stimulation test (DLST) in predicting successful rotation from mesalazine to sulfasalazine (SASP) in patients with UC. Methods: We retrospectively analyzed the largest cohort to date of patients with UC who were suspected of 5-ASA–associated adverse reactions and underwent DLST. We evaluated the DLST positivity rate for the suspected formulation, cross-reactivity to nonsuspected formulations, and clinical outcomes after rotation from mesalazine to SASP. Results: Mesalazine formulations exhibited a DLST positivity rate of 22.0% (18/82), with 45.1% (37/82) of patients testing positive for at least one 5-ASA formulation. Cross-reactivity between mesalazine and SASP was lower at 12.2% (10/82), likely because of structural differences. Adverse reactions typically developed within 2 weeks of initiating 5-ASA and commonly included fever, diarrhea, and bloody stool. Among patients with mesalazine-associated adverse reactions with DLST-negative test result for SASP, 8 of 12 tolerated the rotation. Rotation failure was mainly associated with a positive or borderline DLST result for mesalazine. Conclusions: DLST serves as a useful diagnostic tool for guiding treatment in patients with UC and suspected 5-ASA–associated hypersensitivity reactions. Prospective multicenter studies are needed to validate its clinical utility.

  • Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan.

    Mizushima I, Yoshimatsu Y, Kiyohara H, Sugimoto S, Sujino T, Takabayashi K, Mikami Y, Kanai T

    Intestinal research  2026.02

    ISSN  1598-9100

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Molecular perturbation analysis during tumor formation

    2026.06
    -
    2028.03

    挑戦的研究（萌芽）, Principal investigator

  • Therapeutic repair approaches for small intestinal dysfunction

    2026.04
    -
    2029.03

    日本学術振興会, 科学研究費助成事業, 基盤研究(B), Principal investigator

  • 細胞固有の組織像から紐解く消化器病学

    2025.10
    -
    2032.03

    科学技術振興機構, 戦略的な研究開発の推進 創発的研究支援事業, Principal investigator

  • 小腸オルガノイドを用いた再生医療へ向けた基盤的研究

    2024.07
    -
    2027.03

    国立研究開発法人日本医療研究開発機構, 再生・細胞医療・遺伝子治療実現加速化プログラム, 再生・細胞医療・遺伝子治療研究開発課題（基礎応用研究課題）, Principal investigator

  • Visualization of intestinal lesions in vivo by diseased tissue reconstruction

    2024.06
    -
    2026.03

    挑戦的研究（萌芽）, Principal investigator

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • 医学生・研修医・専攻医の内科学 ことはじめ2026 指導教官賞

    2026.04, 第123回日本内科学会講演会

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 2025年度症例報告最優秀賞専修医部門 指導医

    2026.03, 慶應大学医学部内科学教室

    Type of Award： Keio commendation etc.

  • 第60回日本消化器免疫学会総会奨励賞

    2023.10

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 第31回日本医学会総会奨励賞　内科領域

    2023.04

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 若手奨励賞

    2022.10, 第30回日本消化器関連学会週間（JDDW 2022 FUKUOKA）

    Type of Award： Award from Japanese society, conference, symposium, etc.

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, INTERNAL MEDICINE (GASTROENTEROLOGY)

    2026

  • ADVANCED PHARMACOTHERAPY

    2026

  • LECTURE SERIES, INTERNAL MEDICINE (GASTROENTEROLOGY)

    2025

  • LECTURE SERIES, INTERNAL MEDICINE (GASTROENTEROLOGY)

    2024

  • LECTURE SERIES, INTERNAL MEDICINE (GASTROENTEROLOGY)

    2023

display all >>

Page Top ▲